Abstract: The present invention relates to Siphoviridae bacteriophage Lac-GAP-3 (Accession Number KCTC 12816BP) having the ability to specifically kill Lactococcus garvieae bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention and treatment of Lactococcus garvieae bacterial infection by using a composition containing the same bacteriophage as an effective ingredient.

Abstract: A new promoter comprising: (i) an hCMV enhancer sequence; (ii) an hCMV promoter sequence; (iii) a splice donor region; (iv) a cell-derived enhancer sequence; and (v) a splice acceptor region.

Abstract: The present invention provides methods for treating an individual having bladder cancer comprising intravesically administering to the individual an oncolytic virus. Also provided are pharmaceutical compositions and kits for treating bladder cancer.

Abstract: Disclosed are methods by which compounds/molecules capable of binding antigens, for example antibody type compounds/molecules, can be purified, extracted and/or selected. The methods may be used to purify, extract or select a specific type (or types) of binding agent from a mixed composition. The methods may be used to extract or purify specific binding agents from mixed compositions, which compositions comprise other agents capable of binding other antigens. The methods may find particular application as methods for the purification of blood group antigen antibodies.

Abstract: Chimeric poliovirus is capable of activating antigen presenting cells. The activation of the antigen presenting cells may be in vitro, ex vivo, or in vivo. The activated antigen presenting cells may be administered alone or with an antigen or vaccine. The activated antigen may be loaded in vitro or ex vivo with antigen to form antigen-loaded, activated, antigen presenting cells. These may be administered therapeutically. Therapeutic administration of antigen presenting cells may be used as an adjuvant to other therapies.

Abstract: The present application provides bacteriophage compositions, and methods of treating or preventing bacterial infections using the bacteriophage compositions. The bacteriophage compositions can inhibit bacterial adhesion, invasion, and/or colonization in epithelial cells. The compositions and methods described herein are useful for treating or preventing mastitis in dairy cows.

Abstract: Compositions and methods for detecting influenza are provided.

Abstract: An immunogenic composition forming a vaccine includes a nanoparticle adjuvant comprising at least a nanoparticle, wherein the at least a nanoparticle comprises a lipid layer exterior including a plurality of lipids, cholesterol, and a primary alkyl amine including a positively charged amino group head and at least a carbon tail and an antigen incorporated in the at least a nanoparticle, wherein the antigen comprises a spike protein from a coronavirus.

Abstract: Polyclonal Antibodies produced using HIV-1 Trimeric Envelope Glycoprotein Subunits (TEGS) are provided. TEGS are comprised of non-infectious complexes comprising a trimeric envelope glycoprotein subunit comprising gp120 bound to membrane-anchored trimeric native gp41. The gp120 and gp41 present in the TEGS are not chemically fixed or cross-linked. Immunization with the TEGS elicits polyclonal antibodies that neutralize diverse viruses in HIV infection assay using peripheral blood mononuclear cells (PBMCs). The present invention relates to a method for reducing the occurrence and/or severity of HIV infections.

Abstract: The invention relates, in part, to compounds, compositions, and methods to reduce infectivity of virus particles and to treat viral infections in subjects.

Abstract: Provided are compositions and methods for treating, ameliorating and preventing various infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor, where exemplary compositions are products of manufacture, a food, a drink, a nutraceutical, a dietary supplement, a formulation, a pharmaceutical or a pharmaceutical preparation comprising at least one or several of a plurality of isolated, or substantially purified bacteriophages or prophages, or bacteriophage subunits, a milk, a milk product, milk lipid, milk fat globule (MFG) macromolecule, a milk mucin, a milk glycolipid, a milk free glycan, a milk mucin-like glycoprotein, a milk protein, a milk sugar or lactose, a milk fat or butterfat, a milk vitamin.

Abstract: This disclosure relates to modified viruses, e.g., oncolytic vaccinia viruses, which have been modified to contain an exogenous nucleic acid that expresses a protein that modulates STAT3 activity. It is based, at least in part, on the discovery that vaccinia viruses modified to contain nucleic acid encoding PIAS3 and that express PIAS3 or a fragment thereof can inhibit STAT3 activity and enhance the anti-cancer activity of the vaccinia virus. Accordingly, this disclosure provides for oncolytic vaccinia viruses and methods of using them in the treatment of cancers.

Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Zika virus (ZIKV) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof.

Abstract: The present disclosure is directed towards a virus, called Cedar Virus, and its methods of use.

Abstract: Disclosed is a nanoparticle comprising an inner core comprising a virus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The virus is an oncolytic virus and cellular membrane is derived from for example red blood cells.

Abstract: Modified bacteriophage and compositions containing the modified bacteriophage are described. Exemplary compositions are useful for human treatment and may treat various conditions, including bacterial infections.

Abstract: This document provides methods and materials involved in using measles viruses. For example, methods and materials for identifying mammals (e.g., humans) likely to respond to standard measles virus vaccines or standard measles virus-based therapies as well as methods and materials for identifying mammals (e.g., humans) unlikely to respond to standard measles virus vaccines or standard measles virus-based therapies are provided.

Abstract: The present disclosure provides an antibody capable of binding to an intranuclear protein of an influenza virus and an application thereof. The present disclosure provides an antibody capable of recognizing a peptide consisting of the 205th-231st amino acid sequence in SEQ ID NO: 24.

Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.

Abstract: Provided herein are methods for mapping antibody binding to an immunogen, comprising: immunizing a subject with an immunogen and obtaining sera from the immunized subject at multiple time intervals following immunization, wherein the sera comprises antibodies that are used to form one or more immune complexes with the immunogen; isolating the one or more immune complexes formed by the serum derived antibodies bound to the immunogen; imaging, by electron microscopy, the one or more immune complexes in each of the time intervals, to obtain structural images formed between the immunogen and serum antibodies; determining, from the plurality of structural images, immunogen-antibody binding site for each of the immune complexes obtained at the plurality of time intervals; mapping immunogen-antibody binding by measuring differences in structural images obtained at different time intervals to determine immunogen-antibody binding over multiple time intervals.